Study of the Antiproliferative Activity of a Humanized Antibody to the Cancer-Testis Antigen PRAME

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The PRAME antigen (Preferentially Expressed Antigen in Melanoma), which belongs to the group of cancer-testis antigens and is expressed in various tumor types, represents an attractive target for targeted cancer therapy. In this study, a humanized antibody (6H8Hu) was developed based on the monoclonal antibody 6H8 specific to the PRAME protein. The antibody was produced in CHO cells. It was shown that the humanized antibody retains the high affinity of the parental mAb to the antigen (1.2 nM), binds to both recombinant and native PRAME protein, inhibits the proliferation of PRAME-positive human melanoma cell line Mel Ibr, and suppresses tumor nodule growth in vivo to a degree comparable to that of the murine antibody 6H8 and the cytostatic agent melphalan.

About the authors

M. V Larina

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

Email: marya.larina@gmail.com
Moscow, Russia

Yu. P Finashutina

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

N. A Kravchuk

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

V. A Misyurin

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

V. N Novoseletsky

Biology Department, Shenzhen MSU-BIT University

Shenzhen, China

D. S Balabashin

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

Moscow, Russia

O. N Solopova

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

D. V Sokolova

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

V. S Pokrovsky

N. N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

D. A Dolgikh

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Faculty of Biology, Lomonosov Moscow State University

Moscow, Russia; Moscow, Russia

T. K Aliev

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Faculty of Chemistry, Lomonosov Moscow State University

Moscow, Russia; Moscow, Russia

A. V Misyurin

Yavilov Institute of General Genetics, Russian Academy of Sciences

Moscow, Russia

M. P Kirpichnikov

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Biology Department, Shenzhen MSU-BIT University

Moscow, Russia; Shenzhen, China

References

  1. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G. // Immunity. 1997. V. 6. P. 199–208. https://doi.org/10.1016/s1074-7613(00)80426-4
  2. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., Vissers D.C., ten Bosch G.J., Kester M.G., Sijts A., Wouter Drijfhout J., Ossendorp F., Offringa R., Melief C.J. // J. Exp Med. 2001. V. 193. P. 73–88. https://doi.org/10.1084/jem.193.1.73
  3. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., Dohner K., Schlenk R.F., Pollack J.R., Dohner H., Bullinger L. // Blood. 2006. V. 108. P. 4109–4117. https://doi.org/10.1182/blood-2006-01-023127
  4. Weber G., Caruana I., Rouce R.H., Barrett A.J., Gerdemann U., Leen A.M., Rabin K.R., Bollard C.M. // Clin. Cancer Res. 2013. V. 19. P. 5079–5091. https://doi.org/10.1158/1078-0432.ccr-13-0955
  5. Schneider V., Zhang L., Rojewski M., Fekete N., Schrezenmeier H., Erle A., Bullinger L., Hofmann S., Gotz M., Dohner K., Ihme S., Dohner H., Buske C., Feuring-Buske M., Greiner J. // Int. J. Cancer. 2015. V. 137. P. 2083–2092. https://doi.org/10.1002/ijc.29583
  6. Babiak A., Steinhauser M., Gotz M., Herbst C., Dohner H., Greiner J. // Oncol. Rep. 2014. V. 31. P. 384– 390. https://doi.org/10.3892/or.2013.2804
  7. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., Bergmann L., Schmitt M. // Exp. Hematol. 2000. V. 28. P. 1413–1422. https://doi.org/10.1016/s0301-472x(00)00550-6
  8. Hermes N., Kewitz S., Staege M.S. // Curr. Cancer Drug Target. 2016. V. 16. P. 400–414. https://doi.org/10.2174/1568009616666151222151818
  9. Larina M.V., Finashutina Y.P., Lyzhko N.A., Misyurin V.A., Novoseletsky V.N., Dolgikh D.A., Solopova O.N., Moysenovich A.M., Balabashin D.S., Aliev T.K., Misyurin A.V., Kirpichnikov M.P. // Russ. J. Bioorg. Chem. 2022. V. 48. P. 360–371. https://doi.org/10.1134/S1068162022020133

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russian Academy of Sciences